Use of Physician Global Assessment (PGA) in Systemic lupus erythematosus: a systematic review of its psychometric properties

Chessa, Elisabetta; Piga, Matteo; Floris, Alberto; Devilliers, H.; Cauli, Alberto; Arnaud, Laurent

doi:10.1101/2020.04.14.20064683

Cited by 6 publications

(2 citation statements)

References 103 publications

(314 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…diseases (5)(6)(7)(8)(9)(10)(11)(12)(13)(14). Because performance characteristics of the PhGA may vary by disease, the PhGA should be tested specifically in a cohort of patients with RP.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Physician Global Assessment as a Disease Activity Measure for Relapsing Polychondritis

Rose

Ferrada

Quinn

et al. 2022

Arthritis Care & Research

Self Cite

View full text Add to dashboard Cite

Objective. Relapsing polychondritis (RP) is a systemic inflammatory disorder of cartilage that lacks validated disease activity measures. Our objective was to test physician global assessment (PhGA), a measure of disease activity commonly used in rheumatic diseases, in a cohort of patients with RP, which has not been done before.Methods. Adult patients in an observational cohort of RP underwent standardized, comprehensive evaluation at approximately 6-month intervals. PhGA was scored by 3 physicians from the evaluating institution on a scale of 0-10 for each visit. A random subset of 20 visits was scored by 3 independent physicians not affiliated with the evaluating institution. Treatment change between consecutive visits was categorized as increased, decreased, or unchanged.Results. In total, 78 patients were evaluated over 164 visits. The intraclass correlation coefficient (ICC 2,1 ) for the 3 raters from the evaluating institution was excellent (0.79 [95% confidence interval (95% CI) 0.73, 0.84]) but was poor in the subset of cases scored by the additional raters (ICC 2,1 0.27 [95% CI −0.01, 0.53]). Median PhGA was 3 (range 0-7). PhGA weakly correlated with C-reactive protein level (r s = 0.30, P < 0.01). In response to increased treatment, median PhGA decreased from 3 (interquartile range [IQR] 2, 4) to 2 (IQR 2, 3) (P < 0.01) but rarely went to 0.Conclusion. Within a single center, PhGA can be used to quantify disease activity and monitor disease response in RP. Persistent disease activity despite treatment, rather than a relapsing-remitting pattern, is observed for most patients with RP. Reliability of PhGA may not generalize across different institutions. A validated disease-specific activity index is needed in RP.

show abstract

“…diseases (5)(6)(7)(8)(9)(10)(11)(12)(13)(14). Because performance characteristics of the PhGA may vary by disease, the PhGA should be tested specifically in a cohort of patients with RP.…”

Section: Introductionmentioning

confidence: 99%

“…The PhGA is frequently used to measure disease activity and track response to treatment in a variety of rheumatic diseases (5–14). Because performance characteristics of the PhGA may vary by disease, the PhGA should be tested specifically in a cohort of patients with RP.…”

Section: Introductionmentioning

confidence: 99%